Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Stay away from Normal Traps While Recruiting a Material Organization - 25 Cell phones of the Year
- 3Lucrative Positions in the Advancing Position Market of 2024
- 4The Developing Nearby Food Development and Its Advantages
- 5Flu cases skyrocket in US. See cases, where people got sick.
- RFK Jr.'s vaccine panel delays hepatitis B shot vote after chaotic meeting
- Mickey Lee of 'Big Brother' fame dead at 35 after flu complications, family says
- BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- The most effective method to Look at Medical caretaker Compensations Across Various Clinics
- Crypto Investor’s Family Tied Up and Beaten by Armed Gangs in Their Home
- Rebecca Gayheart on her 'very complicated' relationship with Eric Dane: 'I am always going to want the best for him'
- UAE used military bases in Red Sea region to aid Israel's war against Hamas, leaks reveal
- Support Your Wellness: 20-Minute Home Exercises That Work
